Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.verified

ALGS

Price:

$20.04

Market Cap:

$69.42M

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, i...[Read more]

Industry

Biotechnology

IPO Date

2020-10-16

Stock Exchange

NASDAQ

Ticker

ALGS

The Enterprise Value as of November 2024 (TTM) for Aligos Therapeutics, Inc. (ALGS) is 43.22M

According to Aligos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 43.22M. This represents a change of -63.50% compared to the average of 118.41M of the last 4 quarters.

Aligos Therapeutics, Inc. (ALGS) Historical Enterprise Value (quarterly & annually)

How has ALGS Enterprise Value performed in the past?

The mean historical Enterprise Value of Aligos Therapeutics, Inc. over the last ten years is 8.71B. The current 43.22M Enterprise Value has changed -50.36% with respect to the historical average. Over the past ten years (40 quarters), ALGS's Enterprise Value was at its highest in in the December 2020 quarter at 21.54B. The Enterprise Value was at its lowest in in the March 2018 quarter at 0.

Quarterly (TTM)
Annual

Average

8.71B

Median

7.97B

Minimum

288.33M

Maximum

23.42B

Aligos Therapeutics, Inc. (ALGS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aligos Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 189.58%

Maximum Annual Enterprise Value = 23.42B

Minimum Annual Increase = -91.86%

Minimum Annual Enterprise Value = 288.33M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023288.33M-69.59%
2022948.23M-91.86%
202111.65B-50.23%
202023.42B189.58%
20198.09B3.02%

Aligos Therapeutics, Inc. (ALGS) Average Enterprise Value

How has ALGS Enterprise Value performed in the past?

The current Enterprise Value of Aligos Therapeutics, Inc. (ALGS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

4.30B

5-year avg

8.88B

10-year avg

8.71B

Aligos Therapeutics, Inc. (ALGS) Enterprise Value vs. Peers

How is ALGS’s Enterprise Value compared to its peers?

Aligos Therapeutics, Inc.’s Enterprise Value is greater than CytomX Therapeutics, Inc. (39.67M), greater than Spero Therapeutics, Inc. (-8426888.00), greater than Neoleukin Therapeutics, Inc. (-6333315.00), less than Instil Bio, Inc. (165.40M), greater than NextCure, Inc. (11.01M), less than Assembly Biosciences, Inc. (68.59M), greater than Achilles Therapeutics plc (-38865958.00), less than Nuvation Bio Inc. (923.54M),

CompanyEnterprise ValueMarket cap
39.67M$69.65M
-8426888.00$63.24M
-6333315.00$8.20M
165.40M$170.65M
11.01M$33.33M
68.59M$95.60M
-38865958.00$43.57M
923.54M$942.39M

Build a custom stock screener for Aligos Therapeutics, Inc. (ALGS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aligos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aligos Therapeutics, Inc. (ALGS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aligos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Aligos Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Aligos Therapeutics, Inc. (ALGS)?

What is the 3-year average Enterprise Value for Aligos Therapeutics, Inc. (ALGS)?

What is the 5-year average Enterprise Value for Aligos Therapeutics, Inc. (ALGS)?

How does the current Enterprise Value for Aligos Therapeutics, Inc. (ALGS) compare to its historical average?